Table 2.
Study 1 | Study 2 | Study 3 | |
---|---|---|---|
PLE: n = 262 | CHR: n = 29 | SZ: n = 61 | |
NPLE: n= 1226 | CN: n = 29 | CN: n = 67 | |
Group | F = 0.93, d = 0.06 | F = 2.16, d=0.41 | F = 1.39, d = 0.20 |
Strategy | F = 0.44, d = 0.03 | F = 38.60***, d= 1.67 | F = 29.58***, d = 0.97 |
Group × Strategy | F= 38.22***, d= 0.47 | F= 12.34**, d= 1.26 | F= 6.49*, d= 0.62 |
Post Hoc Oneway ANOVAs | |||
Reappraisal | F = 6.65*, d = 0.13 | F = 12.73**, d = 0.95 | F = 7.84**, d= 0.50 |
Suppression | F= 17.62***, d= 0.22 | F = 1.28, d= 0.30 | F= 1.09, d = 0.19 |
Note.
p < 0.001;
p < 0.01;
p < 0.05.
PLE = individuals with psychotic-like experiences; NPLE = individuals without psychotic-like experiences; CHR = individuals at clinical high-risk; CN = controls; SZ = schizophrenia outpatients.